





























Somatotropic regulation of aging 
 
Although the maximal lifespan of an organism is 
probably genetically determined, the combined accum-
ulative action of different types of stressors, such as 
oxidative damage, telomere attrition and the decline of 
DNA repair and protein turnover systems determines 
the real lifespan and contributes to the so-called aging 
process [1,2]. Currently, the dynamics of aging is far 
from being completely understood, but our knowledge 
of the molecular basis of this complex process has 
considerably increased in recent years. Among the 
different processes and pathways involved in lifespan 
regulation, GH/IGF somatotropic signaling has gained 
relevance as one of the major determinants of longevity 
in different and evolutionary distant species, including 
mammals [3,4]. The pivotal role of somatotropic axis in 
the regulation of lifespan was first shown by Kenyon 
and colleagues, who observed that mutation of specific 
genes essential for IGF-related signaling was able to 
considerably extend longevity in nematodes [5]. Curr-
ently, it is widely accepted that the downregulation of 

































of model organisms and it is also a common feature of 
long-lived individuals [6,7].  
 
Almost two decades after the first evidence on the 
somatotropic axis role in lifespan regulation, many 
other signaling pathways and metabolic routes have 
been shown to participate in the aging process [8-14]. 
Remarkably, some of these advances in the under-
standing of aging have been boosted by the study of 
both accelerated aging syndromes and progeroid animal 
models [15-17]. Progeroid syndromes are dramatic 
diseases in which certain features of human aging are 
prematurely developed, leading to a considerable reduc-
tion in the lifespan of patients, although the specific 
features and impact on longevity are highly dependent 
on the molecular nature of the disease. Many progeroid 
syndromes are caused by defects in DNA repair 
mechanisms but others derive from defects in nuclear 
envelope maintenance [18-21]. In fact, mutations in the 
LMNA gene encoding  lamin A –a fundamental constit-
uent of the nuclear envelope– or in that encoding the 
metalloproteinase ZMPSTE24 involved in the proteolytic 
processing of lamin A– cause dramatic human progeroid  
Rejuvenating somatotropic signaling: a therapeutical opportunity 














Abstract:  We  have  recently  reported  that  progeroid  Zmpste24‐/‐  mice,  which  exhibit  multiple  defects  that  phenocopy
Hutchinson‐Gilford progeria syndrome, show a profound dysregulation of somatotropic axis, mainly characterized by the
occurrence of very high circulating  levels of growth hormone  (GH) and a drastic reduction  in  insulin‐like growth  factor‐1
(IGF‐1).  We  have  also  shown  that  restoration  of  the  proper  GH/IGF‐1  balance  in  Zmpste24‐/‐ mice  by  treatment  with
recombinant  IGF‐1 delays the onset of many progeroid features  in these animals and significantly extends their  lifespan.
Here,  we  summarize  these  observations  and  discuss  the  importance  of  GH/IGF‐1  balance  in  longevity  as  well  as  its
modulation as a putative therapeutic strategy for the treatment of human progeroid syndromes. 
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syndromes, such as Hutchinson-Gilford progeria syndr-
ome (HGPS), atypical Werner syndrome, mandibulo-
acral dysplasia and restrictive dermopathy [20,22,23]. 
The clarification of the molecular mechanisms 


















































lsed by studies of Lmna- and Zmpste24-deficient  
mice, which show nuclear architecture aberrations   
and a number of histopathological alterations that 

























































Figure 1. Proposed model for the somatotroph axis alterations of Zmpste24-/- progeroid mice. Nuclear envelope 
abnormalities present in Zmpste24-deficient cells cause chromatin detachment from the nuclear envelope and a profound structural 
disorganization. This genomic instability activates a chronic DNA damage response, which in turn triggers an adaptive response 
aimed at re-allocating resources from growth to somatic preservation. Hepatocytes are involved in this adaptive response through its 
ability to modulate the somatotropic axis and respond to the chronic DNA damage altering the expression of some key genes that 
affect Igf1-signaling at several levels. First, the reduced growth-hormone receptor (Ghr) transcription and the up-regulation of 
suppressor of cytokine signaling-2 (Socs2), diminishes the Gh-mediated Igf1 transcription. In addition, miR-1 over-activation 
represses Igf1 synthesis, reinforcing the already reduced Igf1 transcription and compromising the circulating levels of Igf1. The 
availability and stability of free Igf1 is reduced through up-regulation of insulin-like growth factor binding protein-1 (Igfbp1) and 
down-regulation of Igfbp-acid labile subunit (Igfals), respectively. Consequently, Igf1- signaling is diminished in the whole 
organism, which in turn leads to a metabolic switch towards somatic maintenance at the expense of somatic growth. In parallel, the 
low levels of Igf1 fail to inhibit Gh secretion at the pituitary gland, generating the high levels of circulating Gh present in these 
progeroid mice, which could aggravate the situation through its deleterious effects. Dotted lines represent disrupted pathways and 
blunt arrows indicate inhibitory actions.  
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Somatotropic signaling in progeria 
 
Given the prominent and evolutionarily conserved role 
of IGF-1-related signaling in lifespan regulation, we 
have recently examined the somatotropic axis in mice 
deficient in the Zmpste24 metalloproteinase, which 
present a strong progeroid phenotype and exhibit many 
features observed in HGPS patients [25]. We have 
found that Zmpste24-/- mice show a profound dys-
regulation of GH/IGF-1 balance, mainly characterized 
by the progressive reduction of blood IGF-1 levels, the 
progressive increase in circulating GH levels and the 
generation of marked transcriptional alterations in key 
genes for somatotropic signaling [27]. In fact, genes 
coding for proteins involved in IGF-1 stability or in 
IGF-1 signaling – such as Igfbals, Ghr, and Igf1 itself– 
are transcriptionally downregulated in livers from 
Zmpste24-deficient mice. Conversely, genes encoding 
proteins involved in IGF-1 signaling suppression such 
as Igfbp1, Socs2 and Socs3 are significantly upregulated 
in progeroid mice, especially in the case of Igfbp1, 
whose mRNA levels are more than 50-fold higher as 
compared with wild-type mice values. The finding of 
these marked alterations of somatotropic axis compon-
ents in Zmpste24-/- mice, and the observation of reduced 
Igf1 mRNA and protein levels even in the presence of 
high circulating GH levels, was indicative of a GH 
resistance process similar to that described in some 
HGPS patients [28]. However, after analyzing the status 
of the main transduction pathways activated by GH in 
response to intravenously injected recombinant GH, we 
excluded the possibility that the transcriptional down-
regulation of IgfI observed in Zmpste24-/- mice is caused 
by a liver-specific GH-resistance derived from signal 
transduction abnormalities in archetypal pathways [27].  
 
Based on these findings, we next explored different 
possibilities which could explain the observed decrease 
of Igf1 mRNA levels in progeroid mice, assuming that 
this should be the initial and major event accounting    
for the dysregulation of somatotropic axis found in 
Zmpste24-/- progeroid mice [27]. After an exhaustive 
search for alterations that could be responsible for the 
observed reduction in IgfI mRNA, we found that miR-1 
–a microRNA predicted to target IgfI– was significantly 
upregulated in a variety of tissues from Zmpste24-/- 
mice. Interestingly, we also observed that this micro-
RNA was significantly upregulated in fibroblasts from 
HGPS patients, which also show profound nuclear 
envelope abnormalities. Since these experimental find-
ings suggested a causal relationship between nuclear 
envelope defects and miR-1 upregulation, we decided to 
characterize in more detail the putative relevance of 
miR-1 as a specific microRNA involved in Igf1 control. 
After performing a series of specific luciferase assays, 
usually employed for microRNAs target validation, we 
could confirm that the 3’-UTR of Igf1 contains a 
functional binding site for miR-1, thereby demon-
strating that miR-1 is a bona fide microRNA targeting 
Igf1 regulator [27,29]. Accordingly, it is tempting to 
speculate that the characteristic nuclear lamina abnor-
malities present in both HGPS and Zmpste24-/- cells 
induce –by a yet unknown mechanism– an upregulation 
of miR-1, which in turn leads to a reduction in Igf1 
mRNA cellular content and finally, to a decrease in 
circulating IGF-1 (Figure 1). As a consequence of this 
decrease, blood GH levels start to rise in an attempt to 
increase IGF-1 synthesis. However, and although GH is 
able to stimulate the IgfI mRNA transcription in 
progeroid cells, the increased levels of miR-1 may 
contribute to block IGF-1 protein synthesis. Taken to-
gether, all these events may initially lead to the obser-
ved dysregulation in the essential GH/IGF-1 balance, 
which in turn probably accounts for all the other 
alterations in somatotropic axis components found in 
Zmpste24-/- progeroid mice (Figure 1).  
 
To test this hypothesis and to evaluate whether a 
restoration of circulating IGF-1 levels in Zmpste24-/- 
mice could have a positive effect on the lifespan and 
progeroid features of these prematurely aged mice, we 
treated mutant mice with recombinant IGF-1 through 
the use of osmotic pumps which allowed a constant and 
stable delivery of the recombinant protein to blood-
stream. Surprisingly, exogenous administration of IGF-
1 not only restored the GH/IGF-1 balance, but also 
significantly extended mutant mice lifespan and 
ameliorated or delayed the onset of many of their 
progeroid features [27]. These findings strongly suggest 
that the dysregulation of somatotropic axis observed in  
Zmpste24-/- progeroid mice is a detrimental pheno-
menon, rather than a successful adaptive strategy.  
 
Concluding remarks and perspectives  
 
Although most of the physiological and pathological 
features of progeroid individuals resemble those found 
in aged individuals, recent studies on prematurely-aged 
mice have facilitated the identification of surprising and 
paradoxical similarities between progeria patients and 
individuals with exceptional lifespan [30,31]. Among 
these similarities, the fact that circulating IGF-1 levels 
of progeroid mice are similar to those observed in long-
lived or calorie-restricted individuals is remarkable, 
given the profound implications of IGF-1 signaling in 
lifespan regulation. Apparently, these paradoxical 
similarities between prematurely-aged and long-lived 
animals could derive from an adaptive effort to adjust 
the values of many biologic parameters to those which 
are compatible with a maximal lifespan, perhaps in an 
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attempt to slow down the onset of premature aging. 
However, the precise physiological significance of these 
surprising alterations has not been studied in detail so 
far. It seems that this kind of metabolic and hormonal 
reprogramming is elicited when DNA damage or chro-
mosomal instability signals reach a certain threshold. In 
fact, similar changes to those observed in prematurely-
aged, calorie-restricted or long-lived individuals in 
terms of somatotropic axis dysregulation are seen in 
wild-type mice subjected to chronic oxidative or 
genotoxic stress [32-34]. It seems reasonable that in 
these conditions, which probably mimic those present in 
progeroid mice, a massive cellular induction of 
checkpoint and anti-proliferative responses would lead 
to a general endocrine and metabolic shift at the 
organismal level. This type of metabolic reprogram-
ming would re-allocate resources from growth to 
somatic preservation in an attempt to reduce replication 
defects, chromosomal instability, nuclear envelope 
abnormalities and finally, the risk of developing cancer 
[31]. Hence, in transient situations of excessive 
genotoxic damage, a systemic metabolic reprogram-
ming towards preservation rather than proliferation 
would be of pivotal importance in order to survive until 
problems are solved. Similarly, during physiological 
aging, DNA damage accumulation would progressively 
induce a similar endocrine and metabolic shift –
although in a much slower fashion– that is only observ-
ed in long-lived individuals who have not succumbed to 
cancer or to any other age-associated diseases.  
 
A similar situation likely applies to individuals 
subjected to calorie restriction regimes, in which 
nutrients scarcity and the subsequent reduction of 
available ATP, would be the driving forces accounting 
for a general metabolic reprogramming which would 
contribute to extend longevity. However, if anti-
proliferative signals are too strong and prolonged in 
time, as presumably occurs in premature aging syndr-
omes, a chronic over-activation of this initially protect-
tive reprogramming could be detrimental for the 
organism, leading to a systemic senescent state and 
finally, to premature death. In this sense, the somato-
tropic axis alterations found in Zmpste24-/- progeroid 
mice represent an example of over-suppression of a 
growth-promoting pathway, as they show multiple and 
probably redundant alterations in regulators of GH-
mediated signaling. In addition, the observed up-
regulation of miR-1 likely contributes to the exacer-
bated suppression of liver IGF-1 synthesis, even in the 
presence of high circulating GH levels. In fact, it is 
possible that these elevated levels of circulating GH 
could directly elicit detrimental responses in peripheral 
tissues, which could contribute to the development of 
accelerated aging. Interestingly, conditional mutant 
mice with liver-specific IgfI-deficiency have reduced 
IGF-1 levels and increased GH circulating levels, as 
well as a series of concomitant metabolic defects that 
can be ameliorated by treatment with a GH antagonist 
[35]. Moreover, giant GH transgenic mice exhibit 
several characteristic features of premature aging [36]. 
Accordingly, it is reasonable to speculate that an 
initially protective response involving a downregulation 
of IGF-1 signaling may lead to detrimental effects when 
it is chronically over-activated and causes a profound 
dysregulation of somatotropic axis.   
 
Our finding that restoration of somatotropic balance by 
recombinant IGF-1 administration not only ameliorates 
several progeroid features of Zmpste24-/- mice, but also 
extends their longevity, strongly supports this hypo-
thesis. Consequently, and although an uncontrolled 
IGF-1 treatment could lead to the massive blockade     
of the anti-proliferative responses characteristic of 
Zmpste24-/- mice and favor cancer development, a selec-
tive modification of some altered signaling pathways 
could be beneficial for extending longevity without 
increasing the risk of malignancies. In this regard, it is 
remarkable that a reduction in p53 signaling increases 
lifespan and delays the onset of progeroid features in 
Zmpste24-/- mice [26]. Thus, given that somatotropic 
axis status is altered in some types of progeria and that 
recombinant IGF-1 treatment is effective for treating 
GH-refractory somatotropic alterations without signify-
cant detrimental effects [37], it is reasonable to consider 
recombinant IGF-1 treatment, alone or in combination 
with other drugs [38], as an experimental therapeutic 
strategy for children with progeria. Further studies with 
improved murine models of human progeria [16] will be 
necessary before this possibility can be translated into a 




This work has been supported by grants from Ministerio 
de Ciencia e Innovación-Spain, Fundación “M. Botín”, 
and European Union (FP7 MicroEnviMet). The Instit-
uto Universitario de Oncología is supported by Obra 
Social Cajastur and Acción Transversal del Cáncer-
RTICC.  
 
CONFLICT OF INTERESTS STATEMENT 
 
The authors of this manuscript have no conflict of 













M,  Heijmans  BT,  Mooijaart  SP,  Blauw  GJ,  Slagboom  PE,  van 
Heemst D. Human  insulin/IGF‐1 and familial  longevity at middle 
age. Aging. 2009; 1: 714‐722. 
5.  Kenyon  C,  Chang  J,  Gensch  E,  Rudner  A,  Tabtiang  R.  A  C. 
elegans  mutant  that  lives  twice  as  long  as  wild  type.  Nature. 
1993; 366: 461‐464. 





8.  Guarente  L  and  Kenyon  C.  Genetic  pathways  that  regulate 
ageing in model organisms. Nature. 2000; 408: 255‐262. 
9.  Espada  J, Varela  I,  Flores  I, Ugalde AP, Cadinanos  J, Pendas 
AM, Stewart CL, Tryggvason K, Blasco MA, Freije JM, Lopez‐Otin 
C.  Nuclear  envelope  defects  cause  stem  cell  dysfunction  in 
premature‐aging mice. J Cell Biol. 2008; 181: 27‐35. 
10.  Finkel  T, Deng CX, Mostoslavsky R. Recent progress  in  the 
biology and physiology of sirtuins. Nature. 2009; 460: 587‐591. 
11.  Kapahi P, Chen D, Rogers AN, Katewa SD, Li PW, Thomas EL, 
Kockel  L. With TOR,  less  is more: a  key  role  for  the  conserved 
nutrient‐sensing  TOR  pathway  in  aging.  Cell  Metab.  2010;  11: 
453‐465. 
12.  Marino  G,  Fernandez  AF,  Lopez‐Otin  C.  Autophagy  and 




14.  Sahin  E  and  Depinho  RA.  Linking  functional  decline  of 
telomeres, mitochondria  and  stem  cells during ageing. Nature. 
2010; 464: 520‐528. 




16. Osorio  FG, Obaya  AJ,  Lopez‐Otin  C,  Freije  JM.  Accelerated 
ageing:  from  mechanism  to  therapy  through  animal  models. 
Transgenic Res. 2009; 18: 7‐15. 
17.  Pegoraro  G  and  Misteli  T.  The  central  role  of  chromatin 
maintenance in aging. Aging. 2009; 1: 1017‐1022. 





responses  in  progeria  arising  from  defective  maturation  of 
prelamin A. Aging. 2009; 1: 28‐37. 
20.   Burtner CR and Kennedy BK. Progeria syndromes and age‐




generate  an  aging‐like  epigenetic  pattern  in  mice  deficient  in 
Zmpste24 metalloprotease. Aging Cell. 2010; 9: 947‐957. 




De  Sandre‐Giovannoli  A,  Levy N. HGPS  and  related  premature 
aging  disorders:  from  genomic  identification  to  the  first 
therapeutic approaches. Mech Ageing Dev. 2008; 129: 449‐459. 
24.   Sullivan T, Escalante‐Alcalde D, Bhatt H, Anver M, Bhat N, 
Nagashima  K,  Stewart  CL,  Burke  B.  Loss  of  A‐type  lamin 
expression  compromises  nuclear  envelope  integrity  leading  to 
muscular dystrophy. J Cell Biol. 1999; 147: 913‐920. 
25.   Pendas AM, Zhou Z, Cadinanos  J, Freije  JM, Wang  J, Hult‐
enby  K,  Astudillo  A, Wernerson  A,  Rodriguez  F,  Tryggvason  K, 
Lopez‐Otin C. Defective prelamin A processing and muscular and 
adipocyte  alterations  in  Zmpste24  metalloproteinase‐deficient 
mice. Nat Genet. 2002; 31: 94‐99. 
26.   Varela  I, Cadinanos  J, Pendas AM, Gutierrez‐Fernandez A, 
Folgueras  AR,  Sanchez  LM,  Zhou  Z,  Rodriguez  FJ,  Stewart  CL, 
Vega  JA,  Tryggvason  K,  Freije  JM,  Lopez‐Otin  C.  Accelerated 
ageing  in mice deficient  in Zmpste24 protease  is  linked  to p53 
signalling activation. Nature. 2005; 437: 564‐568. 
27.   Marino G, Ugalde AP,  Fernandez AF, Osorio  FG,  Fueyo A, 




28.    Abdenur  JE,  Brown  WT,  Friedman  S,  Smith  M,  Lifshitz  F. 




Reciprocal  regulation  of  microRNA‐1  and  insulin‐like  growth 




PM,  Cadinanos  J,  van  der  Pluijm  I,  Freije  JM,  Lopez‐Otin  C. 
Premature  aging  in  mice  activates  a  systemic  metabolic 
response involving autophagy induction. Hum Mol Genet. 2008; 
17: 2196‐2211. 
31. Hoeijmakers  JH. DNA  damage,  aging,  and  cancer. N  Engl  J 
Med. 2009; 361: 1475‐1485. 
32.  Niedernhofer LJ, Garinis GA, Raams A, Lalai AS, Robinson AR, 
Appeldoorn  E, Odijk H, Oostendorp R, Ahmad A,  van  Leeuwen 
W, Theil AF, Vermeulen W, van der Horst GT, Meinecke P, Kleijer 
WJ,  Vijg  J,  Jaspers  NG,  Hoeijmakers  JH.  A  new  progeroid 
syndrome  reveals  that  genotoxic  stress  suppresses  the 
somatotroph axis. Nature. 2006; 444: 1038‐1043. 
33.  van  der  Pluijm  I,  Garinis  GA,  Brandt  RM,  Gorgels  TG, 
Wijnhoven SW, Diderich KE, de Wit J, Mitchell JR, van Oostrom 
C, Beems R, Niedernhofer LJ, Velasco S, Friedberg EC, Tanaka K, 




34.   Garinis GA, Uittenboogaard  LM,  Stachelscheid H,  Fousteri 
M, van Ijcken W, Breit TM, van Steeg H, Mullenders LH, van der 
Horst GT, Bruning JC, Niessen CM, Hoeijmakers JH, Schumacher 
B. Persistent  transcription‐blocking DNA  lesions  trigger  somatic 
  
www.impactaging.com                       1021                      AGING, December 2010, Vol.2 No.12
growth  attenuation  associated  with  longevity.  Nat  Cell  Biol. 
2009; 11: 604‐615. 
35.    Yakar  S,  Setser  J,  Zhao H,  Stannard B, Haluzik M, Glatt V, 
Bouxsein  ML,  Kopchick  JJ,  LeRoith  D.  Inhibition  of  growth 
hormone  action  improves  insulin  sensitivity  in  liver  IGF‐1‐
deficient mice. J Clin Invest. 2004; 113: 96‐105. 
36.  Wolf E, Kahnt E, Ehrlein J, Hermanns W, Brem G, Wanke R. 
Effects of  long‐term elevated  serum  levels of growth hormone 
on  life  expectancy  of  mice:  lessons  from  transgenic  animal 
models. Mech Ageing Dev. 1993; 68: 71‐87. 
37.  Clemmons DR. Modifying IGF1 activity: an approach to treat 
endocrine  disorders,  atherosclerosis  and  cancer. Nat  Rev Drug 
Discov. 2007; 6: 821‐833. 
38. Varela I, Pereira S, Ugalde AP, Navarro CL, Suarez MF, Cau P, 
Cadinanos  J, Osorio  FG,  Foray N,  Cobo  J,  de  Carlos  F,  Levy N, 
Freije  JM,  Lopez‐Otin  C.  Combined  treatment with  statins  and 
aminobisphosphonates extends  longevity  in  a mouse model of 
human premature aging. Nat Med. 2008; 14: 767‐772. 
  
www.impactaging.com                    1022                        AGING, ecember 2010, Vol.2  No.12
